Adaptive Biotechnologies Showcases clonoSEQ Test Clinical Applications at ASH Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Growing Clinical Applications: At the 67th ASH Annual Meeting, Adaptive Biotechnologies showcased 17 abstracts utilizing the clonoSEQ® test, highlighting its critical role in improving blood cancer patient care and driving transformative clinical decision-making.
- EndRAD Study Findings: The Phase II EndRAD study demonstrated that among 51 NGS MRD-negative patients, non-total body irradiation (TBI) regimens yielded comparable survival rates to traditional TBI, indicating a potential reduction in long-term toxicities for children and young adults, which is significant for clinical practice.
- Multiple Myeloma Research: The AURIGA study involving 200 newly diagnosed multiple myeloma patients showed that intensified maintenance therapy doubled MRD negativity rates, emphasizing the correlation between MRD dynamics and progression-free survival, which could influence treatment strategies.
- Leadership of clonoSEQ: Susan Bobulsky stated that the unprecedented volume of data presented at ASH further solidifies clonoSEQ's leadership in blood cancer MRD monitoring, reflecting the test's value in accelerating therapeutic progress and enhancing MRD-informed patient management.
ADPT.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.460
Low
16.00
Averages
19.33
High
22.00
Current: 17.460
Low
16.00
Averages
19.33
High
22.00
Morgan Stanley
Tejas Savant
Equal Weight
maintain
$11 -> $16
2025-11-11
Reason
Morgan Stanley
Tejas Savant
Price Target
$11 -> $16
2025-11-11
maintain
Equal Weight
Reason
Morgan Stanley analyst Tejas Savant raised the firm's price target on Adaptive Biotechnologies to $16 from $11 and keeps an Equal Weight rating on the shares following the company's recent Q3 report.
JPMorgan
Rachel Vatnsdal
maintain
$17 -> $20
2025-11-06
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$17 -> $20
2025-11-06
maintain
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.
Piper Sandler
Overweight
maintain
$15 -> $20
2025-10-15
Reason
Piper Sandler
Price Target
$15 -> $20
2025-10-15
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $20 from $15 and keeps an Overweight rating on the shares. The firm notes it surveyed 59 doctors but focused on the 28 who see blood cancers. From its survey, Adaptive continues to stand out as an underappreciated stock in the MRD space, holding the second-highest revenues and volumes specifically linked to minimal residual disease detection, and serving the most covered lives. Piper believes the company has significant growth potential, projecting approximately 30% increases in both volume over the next few years, driven by expanded EMR adoption, recent strategic partnerships, blood-based testing options, and ongoing clinical trials.
Guggenheim
NULL -> Buy
initiated
$20
2025-09-30
Reason
Guggenheim
Price Target
$20
2025-09-30
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Adaptive Biotechnologies with a Buy rating and $20 price target.
See All Ratings
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did Chad M Robins sell shares worth $3,070,747?
What is the significance of the SEC filing regarding the stock sale?
How might Adaptive Biotechnologies' stock price react to this insider sale?
Will the CEO's stock sale impact investor confidence in the company?